BACKGROUND: Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors such as veliparib are potent sensitizing agents and have been safely combined with DNA-damaging agents such as temozolomide. The sensitizing effects of PARP inhibitors are magnified when cells harbor DNA repair defects. METHODS: A single-arm, open-label, phase 2 study was performed to investigate the disease control rate (DCR) after 2 cycles of veliparib plus temozolomide in patients with metastatic colorectal cancer (mCRC) refractory to all standard therapies. Fifty patients received temozolomide (150 mg/m 2 /d) on days 1 to 5 and veliparib (40 mg twice daily) on days 1 to 7 of each 28-day cycle. Another 5 patients with mismatch repair-deficient (dMMR) tumors were also enrolled. Twenty additional patients were then treated with temozolomide at 200 mg/m 2 /d. Archived tumor specimens were used for immunohistochemistry to assess mismatch repair, phosphatase and tensin homolog deleted on chromosome 10 (PTEN), and O(6)-methylguanine-DNA methyltransferase (MGMT) protein expression levels. RESULTS: The combination was well tolerated, although some patients required dose reductions for myelosuppression. The primary endpoint was successfully met with a DCR of 24% and 2 confirmed partial responses. The median progression-free survival was 1.8 months, and the median overall survival was 6.6 months. PTEN protein expression and MGMT protein expression were not predictors of DCR. There was also a suggestion of worse outcomes for patients with dMMR tumors. 
INTRODUCTION
Treatment options for metastatic colorectal cancer (mCRC) have improved significantly over the last 2 decades, but most patients ultimately experience disease progression and are left without established treatment options. A novel approach to the treatment of mCRC may be targeting a critical DNA repair pathway through the inhibition of poly(adenosine diphosphate ribose) polymerase (PARP). PARP is a nuclear enzyme that plays a critical role in DNA damage repair. [1] [2] [3] Inactive PARP is autoactivated upon binding to damaged DNA and subsequently poly(adenosine diphosphate ribosyl)ates many nuclear target proteins, including those that facilitate the repair of both single-and double-stranded DNA breaks. Thus, PARP inhibition results in less efficient DNA repair after a cytotoxic insult. Colon cancer cells are characteristically genetically unstable and thus should be more dependent on PARP for DNA repair. [3] [4] [5] On the basis of this notion, PARP inhibitors are proposed as sensitizing agents for a variety of DNA-damaging chemotherapeutic agents.
Several prior publications have evaluated the use of singleagent temozolomide in mCRC patients with mixed results. Initially, in one small phase 2 study of a combination of temozolomide and the O(6)-methylguanine-DNA methyltransferase (MGMT) inhibitor lomeguatrib, 3 patients had prolonged stable disease (SD). 13 In addition, a small case series demonstrated activity of temozolomide in mCRC patients with low MGMT expression. 14 In 2013, 2 publications evaluated the use of temozolomide in mCRC patients and MGMT promoter methylation. Hochhauser et al 15 evaluated 37 mCRC patients as part of a larger phase 2 trial, with 1 of 37 patients responding to therapy. In contrast, Pietrantonio et al 16 enrolled 32 mCRC patients with MGMT promoter methylation in a phase 2 trial and demonstrated a 12% response rate with temozolomide.
Importantly, cancer cells with 1 or more DNA repair pathway defects have been shown to be exquisitely sensitive to a PARP inhibitor alone or combined with chemotherapy (ie, synthetic lethality). 17, 18 This has been classically demonstrated in preclinical studies and human trials in the context of BRCA1/2 and a homologous-repair deficiency. [19] [20] [21] [22] In addition, the efficacy of PARP inhibitors has been described in the setting of a phosphatase and tensin homolog deleted on chromosome 10 (PTEN) deficiency. 23, 24 The connection between a PTEN deficiency and the effectiveness of PARP inhibitors is rational because PTEN has been functionally established as a phosphatase that can regulate the phosphoinositide 3-kinase signaling pathway, 25 which has also been linked to maintaining genomic integrity. 26, 27 In fact, it was shown that tumors lacking PTEN exhibited a defect in homologous recombination. 28 Thus, PTEN-deficient cells were hypersensitive to PARP inhibitors in both in vitro and in vivo models. 28 Clinically, a PTEN deficiency is relevant to this study because estimates show that up to 40% of patients with colorectal cancer (CRC) have an absence of PTEN cytoplasmic expression in tumor cells. 29, 30 Furthermore, 5% to 7% of spontaneous mCRCs are characterized by high levels of microsatellite instability (MSI), which is a marker for and occurs as a result of a loss of expression or mutation of mismatch repair (MMR) genes; these are also labeled mismatch repair-deficient (dMMR) tumors. MMR enzyme expression levels can be detected with a very high sensitivity from paraffinembedded tumor samples, and they correlate well with the MSI status. 31 In fact, testing for the MSI status and/or MMR protein deficiency has become standard practice for all patients with colon cancer. 32 Preclinical data have demonstrated that dMMR cells are significantly more sensitive to the combination of veliparib and cisplatin, irinotecan, and temozolomide than MMR-proficient cells. 10, 33 These clinical studies can be considered together with the premise that severe DNA damage, coupled with inhibition of DNA repair mechanisms, would have a significant cytotoxic effect on cancer cells and provide activity in patients. 6, 34, 35 Herein, we present a phase 2 clinical trial of veliparib plus temozolomide in mCRC patients. The primary endpoint was the disease control rate (DCR), and we have analyzed patient tumor samples for MMR enzyme expression, PTEN expression, and MGMT expression to identify a subgroup of patients who are more likely to benefit from this therapeutic combination.
MATERIALS AND METHODS

Patients
Patients with mCRC whose disease had progressed on or who were intolerant of or ineligible for all standard therapies (including regimens containing fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab, and an anti-epidermal growth factor receptor antibody where appropriate) were eligible. (Prior treatment on since-approved regorafenib and TAS-102 was not a requirement.) Patients were aged 18 years, had an Eastern Cooperative Oncology Group performance status score 2, and had adequate organ and bone marrow function (hemoglobin level 9.0 g/dL, absolute neutrophil count 1.5 3 10 9 /L, platelet count 75 3 10 9 /L, serum creatinine level < 1.5 mg/ dL, nonfasting direct bilirubin level 2.5 3 upper limit of normal [ULN] , and alanine aminotransferase/aspartate aminotransferase levels 3 3 ULN in patients without liver metastases and 5 3 ULN in patients with liver metastases). The study protocol, amendments, and informed consent forms were approved by the institutional review board at Georgetown University. Investigators obtained informed consent from each participant or each participant's guardian before screening.
Study Design and Treatment Schedule
This was a single-center, phase 2, open-label study of veliparib plus temozolomide. Veliparib was given at 40 mg twice daily on days 1 to 7 of each 28-day cycle. For patients enrolled in the original protocol cohort, temozolomide was given at 150 mg/m 2 /d orally on days 1 to 5 of each 28-day cycle. The protocol was amended to enroll an additional 20 patients in a high-dose temozolomide cohort (200 mg/m 2 /d orally on days 1-5 of each 28-day cycle). Finally, a third patient cohort, prospectively identified as being deficient in MMR enzyme expression (the Original Article dMMR cohort), was enrolled. This cohort was closed because of slow accrual after 5 patients. Safety assessments were performed weekly for the first 2 cycles and biweekly thereafter. The tumor response was assessed radiographically every 2 cycles (unless clinically indicated to be done sooner) with the Response Evaluation Criteria in Solid Tumors. Study treatment was continued without interruption in the absence of unacceptable toxicity or progressive disease. The primary endpoint was the DCR, which was defined as the percentage of patients with a complete response or partial response (PR) or SD after 2 cycles. Secondary clinical endpoints included the response rate, progression-free survival (PFS), and overall survival (OS).
Correlative Markers of Responses to Therapy
Archived tumor samples were obtained, and freshly cut slides were prepared to perform an immunohistochemistry (IHC) analysis. In addition, patients in the high-dose and dMMR cohorts had fresh, pretreatment tumor biopsies performed. An IHC analysis of the MMR enzymes MLH1, MSH2, MSH6, and PMS2 was performed and scored by clinical pathologists in Clinical Laboratory Improvement Amendments-certified hospital pathology laboratories. IHC was performed for PTEN and MGMT protein expression with standard assays and the following antibodies: anti-PTEN (138G6; Cell Signaling, Danvers, Massachusetts) at a 1:100 dilution and MGMT (sc-56432; Santa Cruz Biotechnology, Dallas, Texas) at a 1:50 dilution. MGMT staining was defined as positive when more than 10% of the tumor cells showed nuclear staining. 36, 37 PTEN loss was defined as >50% of cells showing a loss of cytoplasmic staining, as previously described. [38] [39] [40] Patients were grouped as follows: clinical benefit (those with SD after 2 cycles or a PR) or no clinical benefit (those with progressive disease).
Statistical Analysis
The 50 initial patients were enrolled according to Simon's 2-stage design 41 to differentiate a 25% DCR from a 10% DCR with 90% power and a 1-sided 10% significance level. DCR was defined as the percentage of patients with a complete response or PR at any time or SD at the end of the second cycle. This design continued if 3 or more patients of the first 21 patients had disease control, and successful treatment was concluded if 8 or more patients had disease control. The protocol was later amended to add 2 pilot cohorts of 20 patients each: one for high-dose treatment and another for dMMR patients. The selection of 20 patients for these pilot cohorts was to collect initial data for description only. Patient characteristics, medical features at study entry, and adverse events at least possibly related to the study therapy were tabulated overall and by study cohort. Differences in DCR among subgroups were tested with chi-square tests, with exact calculations used as needed for small sample sizes. OS was defined as the number of months from enrollment until death or last contact. Patients who were alive at the time of the analysis were censored at their last contact. PFS was defined as the number of months from enrollment to progression or death, whichever occurred first. Patients who were alive and progression-free at the time of the analysis were censored at their last tumor assessment. Kaplan-Meier curves are presented for OS and PFS. Analyses were performed with SAS 9.3 (SAS Institute, Inc, Cary, North Carolina), and figures were created with Stata 12.1 (StataCorp LP, College Station, Texas).
RESULTS
Patient Characteristics and Treatment Cohorts
Between September 2009 and May 2012, 75 patients were enrolled (Fig. 1) into the 3 cohorts. The first stage of Simon's 2-stage design continued with 3 patients having SD in the second cycle. After a low rate of toxicities was observed and the success rate of Simon's design was passed in the original 50 patients, the protocol was amended to allow the enrollment of an additional 20 patients at a higher dose of temozolomide; these patients received temozolomide at 200 mg/m 2 daily on days 1 to 5 of each 28-day cycle. Finally, on the basis of preclinical evidence suggesting that patients with defects in MMR gene expression (dMMR) would be more likely to respond to this combination, 10 ,42 a third cohort of prospectively identified dMMR patients was enrolled. The dMMR cohort was meant to enroll 20 patients, but enrollment was stopped after 5 patients because of slow accrual.
Patient characteristics are listed in Table 1 . The median age was 56 years (range, 35-72 years), most patients had an Eastern Cooperative Oncology Group score of 0 or 1 (97%), and 56% of the patients were male. All patients had received standard treatments, including 5-fluorouracil (and/or capecitabine), oxaliplatin, irinotecan, and bevacizumab, with a median of 3 lines of prior therapy (range, 2-7). Of the 67 patients with KRAS testing, 43% had KRAS wild-type tumors, and all of these patients had received prior anti-epidermal growth factor receptor therapy. Three patients, all in the original cohort, were withdrawn before the first restaging: 1 for noncompliance, 1 because of patient choice, and 1 for toxicity. All other patients were taken off the study because of progressive disease. Figure 1 depicts the patient cohorts, screen failures, and reasons for withdrawal.
Suspected Drug-Related Adverse Events
All 75 patients who received treatment were evaluable for adverse events. No grade 5 events occurred. Overall, the combination of veliparib and temozolomide was well tolerated. Most patients experienced mild fatigue, but it was attributed to study therapy in only 25%. Almost half had nausea, but no cases were grade 3 or 4. There were very few other grade 3 or 4 nonhematologic adverse events; they included dysphagia in 1 patient, vaginal hemorrhage in 1 patient, and febrile neutropenia in 1 patient in the high-dose cohort and urinary hemorrhage in 1 patient in the dMMR cohort. The primary toxicity of concern was myelosuppression. In the original cohort, the rate of grade 3 or 4 myelosuppression was very low, and only 10% of the patients experienced treatment changes, with 4 patients delayed because of myelosuppression and 1 patient stopped. One patient in the original cohort had severe pancytopenia and was taken off the study. However, in the high-dose cohort and the dMMR cohort, the rate of significant myelosuppression was higher, with 36% of the patients having grade 3 or 4 anemia, thrombocytopenia, or neutropenia and associated treatment delays. None of the 25 patients in the high-dose and dMMR cohorts were taken off the study because of myelosuppression. In all cases, the myelosuppression was resolved within 1 to 4 weeks. Table 2 provides the number of patients experiencing adverse events by category and cohort that were possibly, probably, or definitely related to the study drug.
Clinical Responses
The primary endpoint was DCR. All patients were evaluable for their response on an intention-to-treat basis ( Table 3) . Two of the 50 original cohort patients had a PR, and 9 more had SD after 2 cycles (DCR, 22%), which was defined as a success by Simon's 2-stage design. In the high-dose cohort, 7 patients had SD after 2 cycles (DCR, 35%). The DCRs in the high-dose and original protocol cohorts revealed no statistically significant increase in the high-dose group (P 5 .26). None of the patients in the dMMR cohort had SD or a PR.
The median OS and PFS for all patients were 6.6 months (95% confidence interval, 5.6-7.4 months) and 1.8 months (95% confidence interval, 1.6-1.9 months), respectively (Table 3 and Fig. 2A,B) . Broken down by cohort, the OS and PFS were 6.7 and 1.8 months, respectively, for the original cohort; 6.2 and 2.0 months, respectively, for the high-dose cohort; and 6.5 and 1.4 months, respectively, for the dMMR cohort (Table 3) . Figure  2C ,D shows no differences among the cohorts in OS (P 5 .81) or PFS (P 5 .14), respectively.
There was no association between DCR and age or sex. Because the KRAS status has been implemented as a predictive marker for CRC therapy, 43 we analyzed whether the KRAS genotype status correlated with DCR, and we found no association (Table 3) . Archived tumor samples were obtained for all patients. In addition, the 20 patients in the high-dose cohort and the 5 patients in the dMMR cohorts underwent fresh tumor biopsies. MMR analysis was available for 76% of the patients (57 of 75) and was determined for 55 patients. Patients with dMMR tumors rather than MMR-proficient tumors had worse PFS (median, 1.8 vs 1.3 months; P 5 .01). The trend held true but was not statistically significant for OS (P 5 .27) or DCR (P 5 .32). Given reports that tumors lacking PTEN exhibit a defect in homologous recombination and are hypersensitive to PARP inhibitors, 44 we examined the association between PTEN expression and DCR. In our patient samples, according to a previously established scoring system, [38] [39] [40] PTEN protein expression was detected mainly at the cytoplasmic level, although occasional nuclear positivity was present. PTEN expression was lost in 39% of the available samples (19 of 49). However, no clear association was evident between a loss of PTEN expression and DCR (Table 3) . Finally, given the previously published association between MGMT expression and responses to 29 (39) 11 (15) 24 (48) 20 (40) 4 (8) 14 (70) 8 (40) 6 (30) 2 (40) 1 (20) 1 (20) Hemoglobin 35 (47) 29 (39) 6 (8) 18 (36) 17 (34) 1 (2) 14 (70) 9 (45) 5 (25) 3 (60) 3 (60) 0 (0) Leukocytes 15 (20) 9 (12) 6 (8) 2 (4) 1 (2) 1 (2) 11 (55) 7 (35) 4 (20) 2 (40) 1 (20) 1 (20) Neutrophils 13 (17) 5 (7) 8 (11) 5 (10) 3 (6) 2 (4) 6 (30) 1 (5) 5 (25) 2 (40) 1 (20) 1 ( (25) 19 (25) 0 (0) 16 (32) 16 (32) 0 (0) 2 (10) 2 (10) 0 (0) 1 (20) 1 (20) 0 (0) Fever 2 (3) 2 (3) 0 (0) 1 (2) 1 (2) 0 (0) 1 (5) 1 (5) 0 ( (48) 36 (48) 0 (0) 24 (48) 24 (48) 0 (0) 10 (50) 10 (50) 0 (0) 2 (40) 2 (40) 0 (0) Vomiting 14 (19) 14 (19) 0 (0) 7 (14) 7 (14) 0 (0) 6 (30) 6 (30) 0 (0) 1 (20) 1 (20) 0 (0) Anorexia 9 (12) 9 (12) 0 (0) 5 (10) 5 (10) 0 (0) 3 (15) 3 (15) 0 (0) 1 (20) 1 (20) 0 (0) Diarrhea 5 (7) 5 (7) 0 (0) 4 (8) 4 (8) 0 (0) 1 (5) 1 (5) 0 ( 3 (4) 0 (0) 2 (4) 2 (4) 0 (0) 1 (5) 1 (5) 0 ( 2 (3) 0 (0) 1 (2) 1 (2) 0 (0) 1 (5) 1 (5) 0 ( Abbreviations: dMMR, mismatch repair-deficient; NOS, not otherwise specified.
temozolomide, [14] [15] [16] we examined MGMT protein expression in our samples. Surprisingly, no association was found between the MGMT status and DCR, OS, or PFS (Table 3) .
DISCUSSION
Patients with advanced refractory mCRC are in desperate need of additional treatment options. PARP inhibitorbased treatments have demonstrated great promise in preclinical models and in several clinical trials, particularly for DNA repair-deficient subtypes of cancers (ie, predominantly ovarian, breast, prostate, and pancreatic cancers). However, preclinical studies and the logical concept that chromosomally unstable or MSI-high cancer cells may benefit from PARP-inhibitor therapies launched us into designing this trial. Previously, we demonstrated that by transfecting cancer cells with a dominant negative PARP-1 construct (ie, inhibiting PARP-1), we sensitized cancer cells to various DNA-damaging agents. 6 From this preclinical work, we hypothesized that combining a PARP inhibitor with a potent DNA-alkylating agent could force a synthetic lethal setting that would provide a therapeutic window targeting genetically unstable CRC cells.
Here we have demonstrated that veliparib plus temozolomide can be safely administered to patients with refractory mCRC. Patients tolerated the combination well and had very little need for treatment delays or dose modification. Given the higher DCR in the high-dose group, we recommend starting future studies at this higher dose with preplanned dose reductions for myelosuppression. This surprisingly contrasts with a similar trial of veliparib plus temozolomide for patients with refractory breast and ovarian cancers, in which the veliparib dose had to be reduced to 30 mg twice daily. 45 We speculate that these patients with breast and ovarian cancer, who had more standard treatment options, were more heavily pretreated. Another possible explanation may be that more of the breast and ovarian cancer patients harbored underlying BRCA1 or BRCA2 mutations. In a patient with an actionable synthetically lethal gene mutation that may render the tumor more sensitive to treatment, the mutation may also cause a greater degree of toxicity to other normal cells that harbor haploinsufficiency with rapid turnover, such as bone marrow stem cells.
We did meet our protocol-defined primary endpoint with a DCR of 24%, and although the high-dose group was only a small subgroup of patients, its DCR of 35% is even more promising. Moreover, our median OS of 6.6 months is certainly promising and worthy of further investigation. Future clinical trials should ideally identify a patient population most likely to benefit from this combination. We were able to assess the impact of potential predictive biomarkers of response from patient tumors. Although not all patient samples could be tested, there were enough samples in each subgroup to perform a reasonable preliminary (ie, hypothesis-generating) statistical assessment (Table 3) . It has been shown that cells with dMMR are significantly more sensitive to the combination of veliparib and cisplatin, irinotecan, and temozolomide than MMR-proficient cells.
10,33 Therefore, we were surprised to find no benefit from treatment in patients with dMMR tumors. In fact, there appeared to be worse outcomes. We are confident that the determination of the MMR status by IHC was not a limiting factor, and the sensitivity of IHC detection for MMR enzyme (protein) loss has been shown to be 95% predictive of true MSI, as classically tested by polymerase chain reaction (PCR) fragment analysis. 31, 46 Instead, the lack of a benefit may have been an unexpected consequence of choosing temozolomide because it has also been shown to be less effective in dMMR cells. 15, 47 In fact, Hochhauser et al 15 demonstrated no clinical activity of temozolomide in patients with dMMR cancers, despite the preselection of MGMT promoter methylation. Our results are consistent with Hochhauser et al's conclusion that MMR enzymatic activity is necessary for temozolomide activity. However, enhanced efficacy in dMMR patients may be seen in patients treated with a PARP inhibitor and another alkylating agent such as oxaliplatin.
We were also optimistic that patients with PTENdeficient tumors would be more likely to respond to treatment. 23, 24, 28, 42, 44 Our hope was based on preclinical evidence showing that tumors lacking PTEN exhibit a defect in homologous recombination. 28, 48 In addition, a PTEN deficiency appeared to be a marker for PARPinhibitor therapy in endometrioid endometrial cancers both in preclinical models and in a case report. 23, 24 Unfortunately, our patient population did not show an association between PTEN loss and a clinical response to 
